Loading clinical trials...
Loading clinical trials...
A Single-centre. Double-blind, Placebo Controlled Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Repeat Doses of Nebulised GSK2269557 in Healthy Male Subjects
Conditions
Interventions
GSK2269557
GSK2269557 matching placebo
Locations
1
United Kingdom
GSK Investigational Site
London, United Kingdom
Start Date
July 24, 2011
Primary Completion Date
March 26, 2012
Completion Date
March 26, 2012
Last Updated
July 25, 2017
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions